Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 3, 2009, Pages 723-734

  De Steenwinkel, J E M ^a   De Knegt, G J ^a   Ten Kate, M T ^a   Van Belkum, A ^a   Verbrugh, H A ^a   Hernandez Pando, R ^b   Van Soolingen, D ^c   Bakker Woudenberg, I A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Animal model; Biomarker; Cytokine; Therapy outcome; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; ISONIAZID; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOMETRY; DISEASE COURSE; FEMALE; GRANULOMA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; INFLAMMATORY INFILTRATE; MOUSE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 70350532141     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200318     Document Type: Article

References (18)

1. World Health Organization. Global Tuberculosis Control, WHO report 2008, Geneva, pp. 1-304.
2. World Health Organization. The Global plan to stop TB 2006-2015, Actions for life, WHO and Stop TB Partnership 2006, Geneva pp. 1-172.
3. Kupeli E, Karnak D, Beder S, Kayacan O, Tutkak H. Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. Respiration 2008; 75:73-78
4. Morosini M, Meloni F, Marone Bianco A, Paschetto E, Uccelli M, Pozzi E, Fietta A. The assessment of IFN-gamma and its regulatory cytokines in the plasma and bronchoalveolar lavage fluid of patients with active pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 7:994-1000. (Pubitemid 37237064)
5. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, van der Poll T. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 1999; 115:110-113 (Pubitemid 29030371)
6. Ilonidis G, Parapanisiou E, Anogeianaki A, et al. Interleukin -1-beta (IL-1-beta), interleukin 6 (IL-6) and tumor necrosis factor (TNF) in plasma and pleural fluid of pneumonia, lung cancer and tuberculous pleuritis. J Biol Regul Homeost Agents 2006; 20:41-46
7. Doherty M, Wallis RS, Zumla A, et al. Biomarkers for tuberculosis disease status and diagnosis. Curr Opin Pulm Med 2009; 15:181-187
8. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4:1931-1939
9. Betts JC, Dodson P, Quan S, Lewis AP, Thomas PJ, Duncan K, McAdam RA. Comparison of the proteome of Mycobacterium tuberculosis strain H37Rv with clinical isolate CDC 1551. Microbiology 2000; 146:3205-3216 (Pubitemid 32040820)
10. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662
11. Hernández-Pando R, Pavón L, Arriaga K, Orozco H, Madrid-Marina V, Rook G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 1997; 65:3317-3327 (Pubitemid 27342417)
12. Bakker-Woudenberg IA. Experimental models of pulmonary infection. J Microbiol Methods 2003; 54: 295-313.
13. Barnes PF, Vankayalapati R. Th1 and Th2 Cytokines in the Human Immune Reponse to Tuberculosis, in Tuberculosis and the Tubercle Bacillus first edition, S.T. Cole, K.D. Eisenach, D.N. McMurray, W.R. Jacobs jr. eds. American Society for Microbiology (ASM) press, Washington, 2005; pp.489-496
14. Hopewell PC, Jasmer RM. Overview of Clinical Tuberculosis in Tuberculosis and the Tubercle Bacillus first edition S.T. Cole, K.D. Eisenach, D.N. McMurray, W.R. Jacobs jr. eds American Society for Microbiology (ASM) press, Washington, 2005; pp. 15-32.
15. Keller C, Lauber J, Blumenthal A, Buer J, Ehlers S. Resistance and susceptibility to tuberculosis analysed at the transcriptome level: lessons from mouse macrophages. Tuberculosis (Edinb) 2004; 84:144-158 (Pubitemid 38857848)
16. Hernández-Pando R, Orozcoe H, Sampieri A, Pavón L, Velasquillo C, Larriva-Sahd J, Alcocer JM, Madrid MV. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89:26-33.
17. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of Sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37:407-413 (Pubitemid 23072581)
18. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169:421-426 (Pubitemid 38134824)